Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
NCT01336933 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2023-09-22
Summary
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Conditions
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Peripheral T-cell Lymphoma
Interventions
- DRUG
-
Given PO
- DRUG
-
Given IV
- DRUG
-
etoposide
Given PO or IV
- DRUG
-
Vincristine
Given IV
- DRUG
-
pralatrexate
Given IV
- OTHER
-
laboratory biomarker analysis
Correlative studies
- GENETIC
-
comparative genomic hybridization
Correlative studies
- GENETIC
-
gene expression analysis
Correlative studies
- GENETIC
-
nucleic acid sequencing
Correlative studies
- GENETIC
-
mutation analysis
Correlative studies
- OTHER
-
immunohistochemistry staining method
Correlative studies
- GENETIC
-
microarray analysis
Correlative studies
- GENETIC
-
RNA analysis
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Spectrum Pharmaceuticals, Inc
collaborator INDUSTRY -
University of Nebraska
lead OTHER
Principal Investigators
-
Julie M Vose · University of Nebraska
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-06
- Primary Completion
- 2016-12-28
- Completion
- 2016-12-28
Countries
- United States
Study Locations
More Related Trials
-
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
NCT00003113 ·Status: TERMINATED ·Phase: PHASE2
-
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00052442 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
NCT00211185 ·Status: COMPLETED ·Phase: PHASE2
-
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003784 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00001337 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
NCT00002488 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
NCT00079105 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00060385 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
NCT00336583 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
NCT04569032 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
NCT00053768 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105 ·Status: UNKNOWN ·Phase: PHASE1
-
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
NCT00621452 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
NCT00002565 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
NCT00005867 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601 ·Status: COMPLETED ·Phase: PHASE2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00074178 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131 ·Status: RECRUITING ·Phase: PHASE3
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
NCT00003388 ·Status: COMPLETED ·Phase: PHASE2
-
Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma
NCT00003501 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057 ·Status: COMPLETED ·Phase: PHASE2